BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1420@pharmaconomics
DTSTAMP:20260707T041756Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:VALN Phase 3 — VLA15
DESCRIPTION:Phase 3 trial results for VLA15 in Lyme disease are due Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1836564/000162828026019159/a2026_03x18xfyx2025xresult.htm\n\nTrack it: https://pharmaconomics.com/e/1420
URL:https://pharmaconomics.com/e/1420
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:VALN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR